XML 59 R40.htm IDEA: XBRL DOCUMENT
v3.24.3

Subsequent Events (Details) - USD ($) $ / shares in Units, $ in Thousands |  |  |  |  |  |  |  |  | 1 Months Ended | 2 Months Ended | 3 Months Ended | 8 Months Ended |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Apr. 30, 2024 | Apr. 12, 2024 | Mar. 31, 2024 | Mar. 22, 2024 | Mar. 07, 2024 | Mar. 06, 2024 | Feb. 06, 2024 | Dec. 31, 2023 | Mar. 31, 2024 | Mar. 31, 2024 | Sep. 30, 2024 | Sep. 30, 2024 | Jun. 15, 2024 | Mar. 05, 2024 | Feb. 29, 2024
Subsequent Events (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of shares granted (in Shares) |  |  |  |  |  |  |  |  |  |  |  |  | 1,287,760 |  |  |
Percentage of development costs |  |  |  |  |  |  |  |  |  |  |  |  | 50.00% |  |  |
Reimburse of development costs |  |  |  |  |  |  |  |  | $ 3,300 |  |  |  |  |  |  |
Research and development expense | [1] |  |  |  |  |  |  |  |  |  |  | $ 25,691 | $ 49,557 |  |  |
Gross proceeds |  |  |  | $ 3,000 |  |  |  |  |  |  |  |  |  |  |  |
Converted into shares value |  |  |  |  |  |  |  |  |  |  |  |  | $ 2,931 |  |  |
Lease term |  |  |  |  |  |  |  |  |  |  |  | 1 year | 1 year | 39 months 15 days |  |
Lease payment |  |  |  |  |  |  |  |  |  |  |  |  | $ 74 |  |  |
Clinical Development Milestones [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Subsequent Events (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable milestone payments |  |  |  |  |  |  |  | $ 12,000 |  | $ 12,000 |  |  |  |  |  |
Certain Regulatory Milestones [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Subsequent Events (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable milestone payments |  |  |  |  |  |  |  | $ 10,000 |  | $ 10,000 |  |  |  |  |  |
Warrant [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Subsequent Events (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of warrant purchase |  |  |  |  |  |  |  | 1.00% |  |  |  |  |  |  |  |
Subsequent Event [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Subsequent Events (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Price per share (in Dollars per share) |  |  |  |  |  |  | $ 0.15 |  |  |  |  |  |  |  |  |
Research initiation fee |  |  |  |  |  |  | $ 800 |  |  |  |  |  |  |  |  |
Percentage of development costs |  |  |  | 50.00% |  |  | 50.00% |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  |  |  |  |  |  |  | $ 900 |  |  |  |  |
Gross proceeds from common stock |  |  |  |  |  |  | $ 50,000 |  |  |  |  |  |  |  |  |
Lease term |  |  | 39 months 15 days |  |  |  |  |  |  |  |  |  |  |  |  |
Lease payment |  |  | $ 1,400 |  |  |  |  |  |  |  |  |  |  |  |  |
Subsequent Event [Member] | Common Stock [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Subsequent Events (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Price per share (in Dollars per share) |  |  |  |  |  |  | $ 12 |  |  |  |  |  |  |  |  |
Subsequent Event [Member] | Option [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Subsequent Events (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of shares granted (in Shares) |  |  |  |  | 399,222 | 779,971 |  |  |  |  |  |  |  |  |  |
Board of Directors [Member] | Subsequent Event [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Subsequent Events (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Restricted stock awards authorized (in Shares) |  |  |  | 1,022,804 |  |  |  |  |  | 1,022,804 | 1,022,804 |  |  |  |  | 1,184,749
Price per share (in Dollars per share) |  |  |  | $ 0.0001 |  |  |  |  |  | $ 0.0001 | $ 0.0001 |  |  |  |  | $ 0.0001
Convertible Notes [Member] | Subsequent Event [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Subsequent Events (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Principal amount |  |  |  |  |  |  | $ 25,000 |  |  |  |  |  |  |  |  |
Converted into shares value |  |  |  |  |  |  | $ 25,000 |  |  |  |  |  |  |  |  |
Interest rate |  |  |  |  |  |  | 12.00% |  |  |  |  |  |  |  |  |
Convertible Notes [Member] | Subsequent Event [Member] | Convertible Note Purchase Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Subsequent Events (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Principal amount |  |  |  |  |  |  | $ 30,000 |  |  |  |  |  |  |  |  |
2024 Plan [Member] | Minimum [Member] | Subsequent Event [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Subsequent Events (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of shares of common stock available for issuance (in Shares) |  |  |  |  |  | 498,789 |  |  |  |  |  |  |  |  | 213,085 |
2024 Plan [Member] | Maximum [Member] | Subsequent Event [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Subsequent Events (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of shares of common stock available for issuance (in Shares) |  |  |  |  |  | 1,179,193 |  |  |  |  |  |  |  |  | 498,789 |
Paragon [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Subsequent Events (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research initiation fee |  |  |  |  |  |  |  | $ 800 |  |  |  |  |  |  |  |
Paragon [Member] | Subsequent Event [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Subsequent Events (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued development costs |  |  |  |  |  |  | $ 5,900 |  |  |  |  |  |  |  |  |
Payment to related party |  | $ 3,300 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Series A Preferred Stock [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Subsequent Events (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Preferred stock, shares issued (in Shares) |  |  |  |  |  |  |  |  |  |  |  | 2,439,000 | 2,439,000 |  |  |
Series A Preferred Stock [Member] | Subsequent Event [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Subsequent Events (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Price per share (in Dollars per share) |  |  |  |  |  |  | $ 0.15 |  |  |  |  |  |  |  |  |
Preferred stock, shares issued (in Shares) |  |  |  |  |  |  | 20,000,000 |  |  |  |  |  |  |  |  |
Gross proceeds |  |  |  |  |  |  | $ 3,000 |  |  |  |  |  |  |  |  |
Stock issuance cost |  |  |  |  |  |  | $ 100 |  |  |  |  |  |  |  |  |
Conversion price per share (in Dollars per share) |  |  |  |  |  |  | $ 0.5712 |  |  |  |  |  |  |  |  |
Series A Preferred Stock [Member] | Convertible Notes [Member] | Subsequent Event [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Subsequent Events (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Principal amount |  |  |  |  |  |  | $ 25,000 |  |  |  |  |  |  |  |  |
Series A Convertible Preferred Stock [Member] | Subsequent Event [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Subsequent Events (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Conversion price per share (in Dollars per share) |  |  |  |  |  |  | $ 0.26 |  |  |  |  |  |  |  |  |
[1] | Includes related party amount of $13,537 for the three months ended September 30, 2024 and $33,967 for the period from February 6, 2024 (inception) to September 30, 2024

X
- Definition Percentage of development costs. + References No definition available. + Details
Name: | orka_DevelopmentCostsPercentage
Namespace Prefix: | orka_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Non-refundable milestone payments. + References No definition available. + Details
Name: | orka_NonRefundableMilestonePayments
Namespace Prefix: | orka_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage of warrant purchase. + References No definition available. + Details
Name: | orka_PercentageOfWarrantPurchare
Namespace Prefix: | orka_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of reimburse of development costs. + References No definition available. + Details
Name: | orka_ReimburseOfDevelopmentCosts
Namespace Prefix: | orka_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the amount of research initiation fee. + References No definition available. + Details
Name: | orka_ResearchInitiationFee
Namespace Prefix: | orka_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- References No definition available. + Details
Name: | orka_SubsequentEventsDetailsLineItems
Namespace Prefix: | orka_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details
Name: | us-gaap_DebtConversionConvertedInstrumentAmount1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Face (par) amount of debt instrument at time of issuance. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details
Name: | us-gaap_DebtInstrumentFaceAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The average effective interest rate during the reporting period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details
Name: | us-gaap_DebtInstrumentInterestRateDuringPeriod
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details
Name: | us-gaap_LesseeOperatingLeaseTermOfContract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details
Name: | us-gaap_OperatingLeasePayments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of expenses incurred but not yet paid classified as other. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details
Name: | us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The cash outflow for cost incurred directly with the issuance of an equity security. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details
Name: | us-gaap_PaymentsOfStockIssuanceCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Per share conversion price of preferred stock. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details
Name: | us-gaap_PreferredStockConvertibleConversionPrice
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details
Name: | us-gaap_PreferredStockSharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition The cash inflow from the additional capital contribution to the entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details
Name: | us-gaap_ProceedsFromIssuanceOfCommonStock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details
Name: | us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details
Name: | us-gaap_RepaymentsOfRelatedPartyDebt
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of shares authorized for issuance under share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Gross number of share options (or share units) granted during the period. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Per share or per unit amount of equity securities issued. + References No definition available. + Details
Name: | us-gaap_SharesIssuedPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_ClinicalDevelopmentMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_CertainRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=orka_ConvertibleNotesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=orka_ConvertibleNotePurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourEquityIncentivePlanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orka_ParagonMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=orka_SeriesAConvertiblePreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |